Syndax unveils mutant-selective EGFR inhibitor SNDX-4321, targets IND filing by end-2026
SNDX•New pipeline programs and development timeline
- Syndax unveiled two new pipeline programs at an R&D event, expanding beyond its late-stage revumenib and axatilimab franchises.
- Introduced SNDX-4321, a mutant-selective allosteric EGFR inhibitor for EGFR-mutated NSCLC; IND filing targeted by end-2026; Phase 1 start in 2027.
- Selected SNDX-62122, a next-generation menin inhibitor, for myelofibrosis; IND filing expected in 2027; Phase 1 planned in 2027.
- Axatilimab Phase 2 trial in idiopathic pulmonary fibrosis remains on track for topline data in 4Q26.
- Revumenib proof-of-principle Phase 1/2 study in myelofibrosis planned to start in 4Q26; initial data expected in 2H27.
